The long non-coding RNA lncFOXO1 suppresses growth of human breast cancer cells through association with BAP1

Xi,Jie; Feng,Jing; Li,Qian; Li,Xia; Zeng,Saitian

doi:10.3892/ijo.2017.3933

The long non-coding RNA lncFOXO1 suppresses growth of human breast cancer cells through association with BAP1

Authors:
- Jie Xi
- Jing Feng
- Qian Li
- Xia Li
- Saitian Zeng
View Affiliations

Affiliations: Department of Gynecology, Cangzhou Central Hospital, Cangzhou, Heibei 061001, P.R. China
Published online on: March 24, 2017 https://doi.org/10.3892/ijo.2017.3933
Pages: 1663-1670

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer, one of the common cancers of women, is the leading cause of death among women below the age of 50 years in western countries. Long non-coding RNAs (lncRNAs) have been shown to be involved in diverse biological processes, both physical and pathological. However, to date, only a few lncRNAs have been functionally identified in breast cancer, and the overall pathophysiological contributions of lncRNAs to breast cancer remain largely unknown. In the present study, we identified a novel lncRNA termed lncFOXO1 through microarray screening. lncFOXO1 is significantly decreased in breast cancer tissues and cell lines and downregulation of lncFOXO1 expression associates with poorer overall survival. Functional assays demonstrated its suppressive role in breast cancer in vivo and in vitro. Mechanistically, lncFOXO1 suppressed the growth of breast cancer by increasing FOXO1 transcription. Moreover, we found that lncFOXO1 associated with BRCA-1-associated protein 1 (BAP1) and regulates its binding and the level of mono-ubiquitinated H2A at K119 (ubH2AK119) at FOXO1 promoter.

View Figures

View References

1	Wilusz JE, Sunwoo H and Spector DL: Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev. 23:1494–1504. 2009. View Article : Google Scholar : PubMed/NCBI
2	Geisler S and Coller J: RNA in unexpected places: Long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 14:699–712. 2013. View Article : Google Scholar : PubMed/NCBI
3	Prensner JR and Chinnaiyan AM: The emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407. 2011. View Article : Google Scholar : PubMed/NCBI
4	Dieli-Conwright CM, Lee K and Kiwata JL: Reducing the risk of breast cancer recurrence: An evaluation of the effects and mechanisms of diet and exercise. Curr Breast Cancer Rep. 8:139–150. 2016. View Article : Google Scholar : PubMed/NCBI
5	Zhao Z, Li S, Song E and Liu S: The roles of ncRNAs and histone-modifiers in regulating breast cancer stem cells. Protein Cell. 7:89–99. 2016. View Article : Google Scholar :
6	Cojocneanu Petric R, Braicu C, Raduly L, Zanoaga O, Dragos N, Monroig P, Dumitrascu D and Berindan-Neagoe I: Phytochemicals modulate carcinogenic signaling pathways in breast and hormone-related cancers. Onco Targets Ther. 8:2053–2066. 2015. View Article : Google Scholar : PubMed/NCBI
7	Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, Zhang Y, Yang L, Zhong X, Wang LP, et al: A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 26:344–357. 2014. View Article : Google Scholar : PubMed/NCBI
8	Rinn JL and Chang HY: Genome regulation by long noncoding RNAs. Annu Rev Biochem. 81:145–166. 2012. View Article : Google Scholar : PubMed/NCBI
9	Takenaka K, Chen BJ, Modesitt SC, Byrne FL, Hoehn KL and Janitz M: The emerging role of long non-coding RNAs in endometrial cancer. Cancer Genet. 209:445–455. 2016. View Article : Google Scholar : PubMed/NCBI
10	Chen QN, Wei CC, Wang ZX and Sun M: Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 8:1925–1936. 2016.PubMed/NCBI
11	Jaouen A, Thivolet-Bejui F, Chalabreysse L, Piaton E, Traverse-Glehen A, Isaac S, Decaussin-Petrucci M, Depaepe L, Fontaine J, Remy I, et al: BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients. Ann Pathol. 36:111–119. 2016.In French. View Article : Google Scholar : PubMed/NCBI
12	Minardi D, Lucarini G, Milanese G, Di Primio R, Montironi R and Muzzonigro G: Loss of nuclear BAP1 protein expression is a marker of poor prognosis in patients with clear cell renal cell carcinoma. Urol Oncol. 34:338.e11–338.e18. 2016. View Article : Google Scholar
13	Nickerson ML, Dancik GM, Im KM, Edwards MG, Turan S, Brown J, Ruiz-Rodriguez C, Owens C, Costello JC, Guo G, et al: Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer. Clin Cancer Res. 20:4935–4948. 2014. View Article : Google Scholar : PubMed/NCBI
14	Sahtoe DD, van Dijk WJ, Ekkebus R, Ovaa H and Sixma TK: BAP1/ASXL1 recruitment and activation for H2A deubiquitination. Nat Commun. 7:102922016. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, He L, Du Y, Zhu P, Huang G, Luo J, Yan X, Ye B, Li C, Xia P, et al: The long noncoding RNA lncTCF7 promotes self-renewal of human liver cancer stem cells through activation of Wnt signaling. Cell Stem Cell. 16:413–425. 2015. View Article : Google Scholar : PubMed/NCBI
16	Bharathy N, Suriyamurthy S, Rao VK, Ow JR, Lim HJ, Chakraborty P, Vasudevan M, Dhamne CA, Chang KT, Min VL, et al: P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma. J Pathol. 240:269–281. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, Lackner M, Amler L, Hampton G, Deininger MW, et al: A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. 30:1493–1501. 2016. View Article : Google Scholar : PubMed/NCBI
18	Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, et al: FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 127:739–748. 2016. View Article : Google Scholar
19	Kim JH, Choi JS and Lee BH: PI3K/Akt and MAPK pathways evoke activation of FoxO transcription factor to undergo neuronal apoptosis in brain of the silkworm Bombyx mori (Lepidoptera: Bombycidae). Cell Mol Biol (Noisy-le-grand). (Suppl 58): OL1780–OL1785. 2012.
20	Lian R, Lu B, Jiao L, Li S, Wang H, Miao W and Yu W: MiR-132 plays an oncogenic role in laryngeal squamous cell carcinoma by targeting FOXO1 and activating the PI3K/AKT pathway. Eur J Pharmacol. 792:1–6. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zeng YB, Liang XH, Zhang GX, Jiang N, Zhang T, Huang JY, Zhang L and Zeng XC: miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1. Cancer Cell Int. 16:632016. View Article : Google Scholar : PubMed/NCBI